Highlights Adeno-associated virus (AAV)-mediated gene therapy can correct Abcb4 deficiency (PFIC3) in mice. By restoring phospholipid transport to bile, cholestasis and liver damage were strongly reduced. Stable transgene expression resulted in long-term correction of the phenotype (26 weeks). Hepatic transgene persistence was achieved by sufficiently reducing hepatocyte proliferation.